Baxter names Andrew Hider as next CEO

Andrew Hider: ©Baxter

Baxter International Inc. announced that Andrew Hider will become its next president and chief executive officer, succeeding interim CEO Brent Shafer. Hider is expected to assume the role no later than Sept. 3, 2025, pending the completion of his current commitments.

Shafer, who has served as chair and interim CEO since February, will transition to the role of independent chair of the board following Hider’s appointment.

Hider brings more than two decades of global leadership experience to the health care company, most recently serving as CEO of ATS Corporation, a provider of automation solutions for industries including life sciences and energy. Under his leadership, ATS nearly doubled its adjusted revenues over five years and achieved a comparable increase in earnings, while the company's stock more than tripled on the Toronto Stock Exchange.

“Andrew is an exceptional leader with a strong track record of operational excellence, disciplined execution and innovation,” Shafer said in a statement. “We are confident he is the right executive to lead Baxter into its next chapter.”

In a statement, Hider said he was drawn to Baxter’s mission-driven culture and its legacy of delivering medically essential products.

“Baxter has undergone a significant transformation over the last few years, refocusing the company and better positioning it for the future,” Hider said. “I look forward to partnering with the board and working alongside my talented future colleagues to accelerate innovation, further enhance our performance and redefine health care delivery while driving sustainable, long-term growth.”

Hider’s prior experience includes executive roles at Taylor Made Group and Danaher Corp., as well as a decade at General Electric. He currently sits on the board of Tennant Co. and holds both a bachelor’s degree in interdisciplinary engineering and management and an MBA from Clarkson University.

Baxter is a global medtech firm known for its portfolio of products supporting critical care, surgical, renal, and hospital-based therapies.